Cardiohep Market Mirum has a strong commercial portfolio in rare liver diseases including LIVMARLI for ALGS and PFIC, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for CTX, indicating ongoing sales opportunities within pediatric and adult hepatology specialties and related rare cholestatic conditions.

Pipeline Upsell Late-stage assets such as volixibat for PSC and PBC, brelovitug for HDV, and MRM-3379 for Fragile X present cross-sell potential to centers already using Mirum products, enabling expansion through combination strategies and expanded indications.

Expansion Momentum Recent regulatory interactions and positive Phase 2b data, plus expansion initiatives like EXPAND, suggest ongoing access opportunities with payers and clinicians seeking new options for refractory rare liver and cholestatic diseases.

Commercial Growth First-quarter 2026 net product sales near $160 million with raised 2026 guidance indicate solid revenue traction and budgetary capacity for field expansion, training, and targeted outreach to hepatology and rare disease centers.

Strategic Partnerships Mirum’s global footprint, patient-community focus, and collaborations across rare disease ecosystems point to potential BD collaborations or licensing discussions with specialty distributors, academic centers, and patient advocacy groups to accelerate access and adoption.